SCHEMBL23767893

SCHEMBL23767893

COC(=O)Cc1ccc(-c2nccc(OCc3ccc(Cl)cc3F)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
TBXA2R P21731 2/20 0.39
PTGS1 P23219 2/20 0.39
CYP2C19 P33261 2/20 0.39
PTGER1 P34995 2/20 0.39
PTGER3 P43115 2/20 0.39
PTGER2 P43116 2/20 0.39
GLP1R P43220 4/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
CCR4 P51679 1/20 0.37
XDH P47989 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30080316 0.89 KDM5A (0.43) KDM5AKDM5BCYP1A2CYP2C9TBXA2R
SCHEMBL30124830 0.89 KDM5A (0.46) KDM5AKDM5BCYP1A2CYP2C9TBXA2R
SCHEMBL23767892 0.89 KDM5A (0.46) KDM5AKDM5BCYP1A2CYP2C9TBXA2R
SCHEMBL23767891 0.89 KDM5A (0.43) KDM5AKDM5BCYP1A2CYP2C9TBXA2R
SCHEMBL25203119 0.84 PTGER1 (0.44) CYP1A2CYP2C9TBXA2RPTGS1CYP2C19
SCHEMBL25544407 0.79 PTGDR2 (0.48) KDM5AKDM5BNPC1RAB9ACCR4
SCHEMBL29141565 0.78 CNR1 (0.42) CYP1A2CYP2C9TBXA2RPTGS1CYP2C19
SCHEMBL23767728 0.78 ALKBH1 (0.47) CYP1A2NPC1ALDH1A1RAB9ACLK4
SCHEMBL30020850 0.78 PTGER1 (0.47) CYP1A2CYP2C9TBXA2RPTGS1CYP2C19
SCHEMBL23458734 0.78 PTGER1 (0.47) CYP1A2CYP2C9TBXA2RPTGS1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
CN-115697999-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-02-03 CN disclosed
WO-2021160127-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR KDM5A 3899/4885KDM5B 3787/4885CYP1A2 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.